Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 6,100 shares, an increase of 125.9% from the November 30th total of 2,700 shares. Based on an average daily trading volume, of 9,000 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.1% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Armata Pharmaceuticals in a research report on Thursday, December 19th.

Armata Pharmaceuticals Stock Performance

ARMP stock opened at $2.11 on Friday. The company has a market cap of $76.34 million, a PE ratio of -1.29 and a beta of 0.78. Armata Pharmaceuticals has a one year low of $1.85 and a one year high of $4.48.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.